Vildagliptin and Endothelium-dependent Vasodilatation
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Rationale: Cardiovascular complications in type 2 diabetes are the leading cause of morbidity
and mortality associated with the disease. Endothelial dysfunction is regarded as an
important factor in these vascular complications.
The introduction of glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase IV
(DPP-IV) inhibitors for the treatment of type 2 diabetes is of special interest because of
possible influences on endothelial function. Numerous reports have shown that GLP-1 improves
endothelial function.
Objective: To determine whether a four week treatment with vildagliptin compared to acarbose
improves endothelial dysfunction in patients with type 2 diabetes mellitus.